Hospital Arnau de Vilanova, Lleida, Spain.
Leuk Res. 2013 Jul;37(7):769-76. doi: 10.1016/j.leukres.2013.04.010. Epub 2013 Apr 29.
The prognosis of chromosome 17 (chr17) abnormalities in patients with primary myelodysplastic syndrome (MDS) remains unclear. The revised International Prognostic Scoring System (IPSS-R) includes these abnormalities within the intermediate cytogenetic risk group. This study assessed the impact on overall survival (OS) and risk of acute myeloid leukemia transformation (AMLt) of chr17 abnormalities in 88 patients with primary MDS. We have compared this group with 1346 patients with primary MDS and abnormal karyotype without chr17 involved. The alterations of chr17 should be considered within group of poor prognosis. The different types of alterations of chromosome 17 behave different prognosis. The study confirms the intermediate prognostic impact of the i(17q), as stated in IPSS-R. The results of the study, however, provide valuable new information on the prognostic impact of alterations of chromosome 17 in complex karyotypes.
原发性骨髓增生异常综合征（MDS）患者 17 号染色体（chr17）异常的预后尚不清楚。修订后的国际预后评分系统（IPSS-R）将这些异常归入中细胞遗传学风险组。本研究评估了 88 例原发性 MDS 患者 chr17 异常对总生存（OS）和急性髓系白血病转化（AMLt）风险的影响。我们将该组与 1346 例伴有异常核型但不涉及 chr17 的原发性 MDS 患者进行了比较。chr17 的改变应被视为预后不良组的一部分。不同类型的 chr17 改变具有不同的预后。该研究证实了 IPSS-R 中 i（17q）的中间预后影响。然而，研究结果提供了有关复杂核型中 chr17 改变对预后影响的有价值的新信息。
